LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 72

Search options

  1. Article ; Online: Cannabis Use: A Marker of Clinical Severity in Inflammatory Bowel Disease?

    Erridge, Simon / Sodergren, Mikael H

    Inflammatory bowel diseases

    2023  Volume 30, Issue 2, Page(s) 322–323

    MeSH term(s) Humans ; Cannabis ; Longitudinal Studies ; Inflammatory Bowel Diseases/diagnosis ; Cannabinoids
    Chemical Substances Cannabinoids
    Language English
    Publishing date 2023-09-22
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izad221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users.

    Ciesluk, Beata / Erridge, Simon / Sodergren, Mikael H / Troup, Lucy J

    Frontiers in psychology

    2024  Volume 14, Page(s) 1279123

    Abstract: There is a paucity of research, especially in the UK, that investigates individual differences in both medical and recreational cannabis users. A cross-sectional survey study design was used to assess recreational cannabis users and medical cannabis ... ...

    Abstract There is a paucity of research, especially in the UK, that investigates individual differences in both medical and recreational cannabis users. A cross-sectional survey study design was used to assess recreational cannabis users and medical cannabis users currently living in the UK. Recreational cannabis users were invited to take part via social media. Medical cannabis users were recruited from Sapphire Medical Clinics, London, UK, which provides treatment with prescribed cannabis-based medicinal products. Demographic data and cannabis use frequency, as well as post-traumatic stress disorder symptoms (PCL-5), depression symptoms (Centre for Epidemiological Studies Depression Scale), trait and state anxiety (State-Trait Anxiety Inventory), and cannabis use motives [Comprehensive Marijuana Motives Questionnaire (CMMQ)] were collected. The Chi-square and independent-sample
    Language English
    Publishing date 2024-01-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2563826-9
    ISSN 1664-1078
    ISSN 1664-1078
    DOI 10.3389/fpsyg.2023.1279123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Corrigendum: Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users.

    Ciesluk, Beata / Erridge, Simon / Sodergren, Mikael H / Troup, Lucy J

    Frontiers in psychology

    2024  Volume 15, Page(s) 1368554

    Abstract: This corrects the article DOI: 10.3389/fpsyg.2023.1279123.]. ...

    Abstract [This corrects the article DOI: 10.3389/fpsyg.2023.1279123.].
    Language English
    Publishing date 2024-02-13
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2563826-9
    ISSN 1664-1078
    ISSN 1664-1078
    DOI 10.3389/fpsyg.2024.1368554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: UK Medical Cannabis Registry: A Patient Evaluation.

    Tait, James / Erridge, Simon / Sodergren, Mikael H

    Journal of pain & palliative care pharmacotherapy

    2023  Volume 37, Issue 2, Page(s) 170–177

    Abstract: The UK Medical Cannabis Registry is the largest real world data platform for medical cannabis outcomes in the UK, providing insight into clinical outcomes and monitoring safety of this novel therapy. This study aims to assess the functionality and ... ...

    Abstract The UK Medical Cannabis Registry is the largest real world data platform for medical cannabis outcomes in the UK, providing insight into clinical outcomes and monitoring safety of this novel therapy. This study aims to assess the functionality and accessibility of the online data collection platform and patient priorities for future research. Descriptive statistics were used to analyze quantitative data. For open-ended questions an inductive thematic analysis was performed. 600 responses were recorded. 554 (92.3%) patients had used the platform. 272 (90.4%) patients believed it was easy to input medications. 52 (8.67%) patients recorded an adverse event with 38 (73.1%) finding it easy to record. 535 (96.6%) patients had completed health questionnaires with 490 (91.6%) patients finding this easy to do. 553 (92.2%) patients agreed that contributing to the registry would impact the medical care of future patients. "Assessing the impact of medical cannabis on quality of life generally" was the top research priority for 357 (59.3%) patients. This study demonstrates that most enrolled patients found the platform easy to use and believed they were positively impacting future medical cannabis patient care. Future patient research priorities included assessment of quality of life and condition-specific outcomes.
    MeSH term(s) Humans ; Medical Marijuana/adverse effects ; Quality of Life ; Registries ; Surveys and Questionnaires ; United Kingdom
    Chemical Substances Medical Marijuana
    Language English
    Publishing date 2023-02-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2078852-6
    ISSN 1536-0539 ; 1536-0288
    ISSN (online) 1536-0539
    ISSN 1536-0288
    DOI 10.1080/15360288.2023.2174633
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Letter to the editor: reflections on the future of medical cannabis research for depression.

    Erridge, Simon / Mangoo, Sajed / Sodergren, Mikael H

    Expert review of neurotherapeutics

    2023  Volume 23, Issue 5, Page(s) 481–482

    MeSH term(s) Humans ; Cannabis ; Medical Marijuana/therapeutic use ; Depression/drug therapy ; Hallucinogens
    Chemical Substances Medical Marijuana ; Hallucinogens
    Language English
    Publishing date 2023-04-20
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1080/14737175.2023.2203862
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The Clinical Translation of α-humulene - A Scoping Review.

    Dalavaye, Nishaanth / Nicholas, Martha / Pillai, Manaswini / Erridge, Simon / Sodergen, Mikel H

    Planta medica

    2024  

    Abstract: α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humulene's evidence base, informing clinical translation and ... ...

    Abstract α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humulene's evidence base, informing clinical translation and guiding future research directions. A scoping review was conducted of EMBASE, MEDLINE and PubMed databases up to 14th July 2023. All studies describing original research on α-humulene extraction, pre-clinical and clinical research were included for review. Three-hundred and forty articles were analyzed. α-humulene yields ranged from negligible to 60.90% across plant species. In vitro experiments demonstrated cytotoxicity against adenocarcinomas (such as colorectal, pulmonary, breast, prostatic, lung, and ovarian), with varying responses in other cell models Mechanistic insights revealed its involvement in mitochondrial dysfunction, diminished intracellular glutathione levels, and the induction of oxidative stress. In rodent studies, oral administration of α-humulene at 50 mg/kg reduced inflammation markers in paw edema and ovalbumin-induced airway inflammation. Intraperitoneal administration of α-humulene (50-200 mg/kg) exhibited cannabimimetic properties through cannabinoid 1 and adenosine A2a receptors. α-humulene also exhibited a multitude of properties with potential scope for therapeutic utilization. However, there is a paucity of studies which have successfully translated this research into clinical populations with the associated disease. Potential barriers to clinical translation were identified, including yield variability, limited isolation studies, and challenges associated with terpene bioavailability. Consequently, rigorous pharmacokinetic studies and further mechanistic investigations are warranted to effectively uncover the potential of α-humulene.
    Language English
    Publishing date 2024-04-16
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 123545-x
    ISSN 1439-0221 ; 0032-0943
    ISSN (online) 1439-0221
    ISSN 0032-0943
    DOI 10.1055/a-2307-8183
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Medical cannabis, CBD wellness products and public awareness of evolving regulations in the United Kingdom.

    Erridge, Simon / Coomber, Ross / Sodergren, Mikael H

    Journal of cannabis research

    2022  Volume 4, Issue 1, Page(s) 56

    Abstract: Background: In the UK, legislation and regulations governing medical cannabis and over the counter cannabidiol (CBD) wellness products have rapidly evolved since 2018. This study aimed to assess the public awareness of the availability, regulations, and ...

    Abstract Background: In the UK, legislation and regulations governing medical cannabis and over the counter cannabidiol (CBD) wellness products have rapidly evolved since 2018. This study aimed to assess the public awareness of the availability, regulations, and barriers to access medical cannabis and over the counter CBD wellness products.
    Methods: A cross-sectional survey study was performed through YouGov® using quota sampling methodology between March 22nd and March 31st 2021. Responses were matched and statistically weighted to UK adult population demographics, including those without internet access, and analysed according to percentage of respondents. Statistical significance was defined by p-value < 0.050.
    Results: Ten thousand six hundred eighty-four participants completed the survey. 5,494 (51.4%) respondents believed that medical cannabis is legal in the UK. 684 (6.4%) participants consumed CBD for wellness reasons, 286 (2.7%) were prescribed CBD for a medical reason and 222 (2.1%) consumed CBD for another reason. 10,076 (94.3%) respondents were unaware of April 2021 regulations meaning that all over the counter CBD wellness products in the UK must conform to European Novel Foods Regulations. The most frequently reported main barriers to accessing medical cannabis were its association with recreational cannabis (n = 2,686; 25.1%), being unsure if it was legal (n = 2,276; 21.3%) and being unsure what medical conditions its can be used for (n = 1,863; 17.4%).
    Conclusion: A large proportion of respondents are unaware of the legislation and regulations surrounding medical cannabis and over the counter CBD wellness products. Lack of knowledge may present a barrier to safe access to either product.
    Language English
    Publishing date 2022-10-29
    Publishing country England
    Document type Journal Article
    ISSN 2522-5782
    ISSN (online) 2522-5782
    DOI 10.1186/s42238-022-00165-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Patient priorities for research: A focus group study of UK medical cannabis patients.

    Erridge, Simon / Olsson, Fabian / Sodergren, Mikael H

    Complementary therapies in clinical practice

    2022  Volume 50, Page(s) 101693

    Abstract: Introduction: There has yet to be an evaluation of medical cannabis patient preferences with respect to future research. As such, prioritisation of research agendas has been largely driven by academia and industry. The primary aim of this study was to ... ...

    Abstract Introduction: There has yet to be an evaluation of medical cannabis patient preferences with respect to future research. As such, prioritisation of research agendas has been largely driven by academia and industry. The primary aim of this study was to elicit priorities for research from medical cannabis patients in the United Kingdom (UK).
    Methods: Patients undergoing active treatment for health conditions with medical cannabis in the UK were invited to take part in focus groups from December 2021 to February 2022. An inductive thematic analysis of responses was performed. Participants also completed a ranking exercise whereby they assigned ten counters (each equivalent to £1 million GBP) to competing research priorities.
    Results: 30 medical cannabis patients participated across 3 focus groups. The following themes were identified as research priorities: adverse events, comparison between cannabis-based medicinal products, health conditions, pharmacology of cannabis, types of study, healthcare professionals' attitudes, social environment, agriculture and manufacturing, and the cannabis plant. Participants assigned the highest proportion of research funding to 'assessment of effect on specific symptoms' (26 counters; 8.7%).
    Conclusions: This study highlighted specific themes within which to focus future research on medical cannabis. Clinically, there was a directive towards ensuring that research is condition- or symptom-specific. Participants also emphasised themes on the social impact of medical cannabis, such as knowledge of medical cannabis among healthcare professionals, stigma, and effects on driving and in the workplace. These findings can guide both research funders and researchers into effectively conducting research which fits within a more patient-centric model.
    MeSH term(s) Humans ; Medical Marijuana/therapeutic use ; Cannabis ; Focus Groups ; Health Personnel ; United Kingdom
    Chemical Substances Medical Marijuana
    Language English
    Publishing date 2022-11-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 2182834-9
    ISSN 1873-6947 ; 1744-3881
    ISSN (online) 1873-6947
    ISSN 1744-3881
    DOI 10.1016/j.ctcp.2022.101693
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: eLogbook in surgical training: Time to embrace video? An invited commentary on "Use of the eLogbook in surgical training in the United Kingdom: A nationwide survey and consensus recommendations from the Association of Surgeons in Trainingˮ.

    Erridge, Simon / Purkayastha, Sanjay

    International journal of surgery (London, England)

    2020  Volume 77, Page(s) 114–115

    MeSH term(s) Consensus ; Education, Medical, Graduate ; Humans ; Surgeons ; Surveys and Questionnaires ; United Kingdom
    Language English
    Publishing date 2020-03-28
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2212038-5
    ISSN 1743-9159 ; 1743-9191
    ISSN (online) 1743-9159
    ISSN 1743-9191
    DOI 10.1016/j.ijsu.2020.03.042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.

    Erridge, Simon / Sodergren, Mikael H

    Hepatobiliary surgery and nutrition

    2019  Volume 8, Issue 3, Page(s) 298–300

    Language English
    Publishing date 2019-06-11
    Publishing country China (Republic : 1949- )
    Document type Editorial ; Comment
    ZDB-ID 2812398-0
    ISSN 2304-389X ; 2304-3881
    ISSN (online) 2304-389X
    ISSN 2304-3881
    DOI 10.21037/hbsn.2019.01.17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top